chrisvoncsefalvay/vaers-outcomes huggingface dataset:
EXPIRED VACCINE ADMINISTERED; This spontaneous report received from a pharmacist concerned a 28 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient had no illness at the time of vaccination, no history of similar event, no adverse event after any previous vaccination (s), no history of allergy to vaccine, drug, or food, no pre-existing acute illness 30 days prior to vaccination, no history of hospitalization in last 30 days, with cause and no family history of any disease (relevant to vaccination) or allergy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 211A21A expiry: 14-DEC-2021) dose was not reported, administered on 27-DEC-2021 for prophylactic vaccination. No concomitant medications were reported.  On 27-DEC-2021, the patient experienced expired vaccine administered. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired vaccine administered was not reported. This report was non-serious. This case, from the same reporter is linked to 20220210382, 20220260967, 20220261042, 20220261011, 20220261063, 20220261048, 20220261092, 20220261039, 20220261022, 20220261000, 20220261030, 20220260995, 20220261043 and 20220260995.
This spontaneous report was received from a physician via company representative, concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported. On 18-JAN-2016, the patient was vaccinated with an improperly stored dose of PNEUMOVAX (lot number L024129; expiration date 21-JAN-2017) "10 Pk 0.5 ml SD-PFS LLok w tip" (route of administration and anatomical location were not reported). On an unspecified dates, the PNEUMOVAX 23 had one temperature excursion of 120 hors. The highest recorded temperature was 34 F (1.1111111111 Celsius). No adverse effects reported and no product quality complaint was involved. The vaccine status was reported as "in excursion". The vaccine storage criteria and the storage type of excursion were reported as "Refrigerator (R)". This is one of several cases from the same reporter. Additional information has been requested.
Constant intense itching to palms hands and feet. Red spots to palms of hands. Red rash to upper left back near shoulder, scattered red, itchy bumps to body. This was in addition to expected side effects of fever over 101, weakness, dizziness, nausea, chills,  and redness, swelling, pain. and heat to left arm above the elbow.
4MAY96 vax given & 7MAY96 swelling, redness & tenderness of upper arm
redness and swelling in arm; redness in arm; swelling in arm; itching in arm; Initial information received on 27-Sep-2021 regarding an unsolicited valid non-serious case from a consumer/non-healthcare professional.  This case involves a patient (unknown age and gender) who had redness and swelling (inflammation) and itching (pruritus) in arm after receiving QUADRIVALENT RECOMBINANT INFLUENZA VACCINE (FLUBLOK QIV).  The patient's past vaccination(s) included annual influenza vaccine (lot number and expiration date were not reported) via unknown route in an unknown administration site for prophylactic vaccination, without having any adverse reactions.  It was unknown if the patient had any medical history, concomitant disease or risk factor.  The patient's past medical treatment(s), concomitant medication(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect FLUBLOK QIV (lot number and expiration date were not reported) via unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious redness and swelling (inflammation), redness (erythema), swelling (peripheral swelling) and itching (pruritus) in arm, (unknown latency) following the administration of vaccine.  It was unknown if the patient experienced any additional symptoms/events.  It was unknown if there were laboratory data/results available.  It was not reported if the patient received a corrective treatment.  At time of reporting, the outcome was unknown for the reported events.  There will be no information available on the batch number for this case.
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age. The patient was vaccinated with the first and second dose of GARDASIL (lot number not provided) on 11-AUG-2011 and on 13-AUG-2012 the patient was in the office to receive the second dose. No other co-suspects were reported. No concomitant medications were reported. It was unspecified if the patient had sought medical attention. Additional information is not expected.
This spontaneous report was received from a registered nurse referring to unspecified patients of unknown ages and genders. The patients' pertinent medical history, drug reactions, allergies and concomitant medications were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of PROQUAD, lot numbers M041082, expiry date 04-APR-2018; M042502, expiry date 17-APR-2018; and M046943, expiry date 27-MAY-2018 (strength, dose, frequency and route of administration were not provided) for prophylaxis. The vaccines were administered along with a sterile diluent (MRK) that was properly stored. Administered vaccines experienced a temperature excursion between 6°F and 14°F during 2 hours and 20 minutes. There was a previous temperature excursion (duration and temperatures were not reported). Digital data logger was involved. No adverse effects were reported. No product quality complaint (PQC) was involved. Additional information has been requested.
p/vax pt devel wheezing, chest tightness & facial flushing;tx w/DPH & epi & 02;sx resolved w/in 3min;this event is considered medically important;
49 YO Female presented w c/o left upper arm redness/pain x48 hours. Had Tdap 5/30/12 and experienced localized injection site soreness that resolved 6/2/12. However 6/4/12 noticed Left delt injection site pain had returned followed by increased edema. Today, 6/7/12, edema had further increased per verbal report.
Information has been received from a registered nurse referring to an unspecified number of unspecified patients. On unknown dates, the patients were vaccinated with doses of improperly stored VAQTA (Lot#: K005958, expiry date: 09-FEB-2017; K007791, expiry date: 22-AUG-2016; K018182, expiry date: 12-FEB-2017; K019560, expiry date: 02-JUN-2017, exposure on 57 F for 85.75 hours from 22-APR-2015 to 29-NOV-2015; L002717, expiry date: 02-JUN-2017; L009445, expiry date: 01-JUN-2017; L018499, expiry date: 25-FEB-2017; K018181, expiry date: 04-JUN-2017). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Reaction began w/hives then patient refused to stand/walk-cried and fell down. Due to damage of muscular nerve fibers at injection site there is weakness & inflammation causing a limp and misalignment of hips. Injection site still sore.
Diarrhea, vomiting, headaches, severe pain on injection site (from shoulder to elbow), fever, chills.
1 to 1 1/2 hours after injection, I developed rapid heartbeat, swelling of throat, hives on face and neck., and stomach ache. This lasted just over an hour. The next day, I ran 102 fever for 6 hours.
Case number PHEH2015US020517, is an initial spontaneous report from a pharmacist received on 09 Oct 2015. This report refers to a 59-year-old female patient. Historical conditions were not reported. No concomitant medication was reported. The patient was vaccinated with FLUCELVAX (batch number: 174271, expiration date: May 2016) on 28 Sep 2015 (approximately). On 02 Oct 2015, four days after vaccination, the patient experienced a delayed reaction and developed dermatitis that started at the injection site. Final outcome, seriousness and causality were not reported. Seriousness of the event vaccination site dermatitis was upgraded based on information available in the source document.
Chills; slightly sore at injection site; nausea; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via unspecified route of administration in the left arm on 25Mar2021 at 10:00 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not take receive any other medication within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021 at 20:00, the patient experienced chills, slightly sore at injection site and nausea. No therapeutic measures were taken as a result of the events. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  The clinical outcome of the events chills, vaccination site pain and nausea were unknown at the time of this report.   No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
I had an elevated CMV show up almost a year after vaccination, one month after last vaccine.  Then a friend of mine ended up in hospital with liver disease at the same time. The only thing different in our lives was the vaccine.
Moderna vaccine booster (0.25 ml)  dose was inadvertently administered instead of the full dose (0.5 ml)  for the second dose
Developed palpitations and dyspnea about 8 mins after vaccine. Was treated with Benadryl. Seen at my clinic 45mins later. No symptoms and feeling fine
Started feeling sciatic nerve pain in right side of body, mainly with arm and foot.  Called Dr and she said they were nerve symptoms. Has a history of Nerve Pain, Dr. advised to take prescribed Muscle Relaxers. Was told to give it time and see if it resolved and it did.
pt recv vax & 2hr post vax & exp nausea; 1/2 hr later the nausea inc & exp vomiting, syncope & hypotension throughout the PM;also anorexic & weak;
Tingling on one side of face and inside one side of mouth and tongue with small amount of swelling on that side of face, mouth and felt like tiny bit in ear. Woozy and not able to think very well within a few minutes. Nauseas on way home. Tingling etc went away by that evening, a little nausea off and on for about a week, fatigue went away on 10th day and a bit  minded over after about 5 days or so. On 12th day flutters and abdomen pain which went away by day 14.
I experienced my blood boiling under the skin (left leg), my left collar bone start itching under the skin and it also crossed over to the right side.
Since recieving the vaccinations starting in 1999 I have been slowing, and progressively, been getting these symptoms. All over body aches, pain to the touch, difficulty remembering, joint pain, rash/excessive drying on knuckles, rosecea, chronic fatigue, difficulty breathing, vertigo.
Patient states she had a headache across whole head with nausea 2 hours post vaccination. Took tylenol had no relief, then went to bed and felt fine.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. In 2013, the patient was inoculated with ZOSTAVAX at the pharmacy as recommended for routine adult health maintenance for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster or shingles. On or about 13-DEC-2014, the patient was treated by the health care system for a persistent and severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
Pt received the first dose of the Moderna COVID-19 vaccine on 4/5/2021.  On 4/14/2021, he tested positive for SARS-CoV-2 via PCR.  On 4/21/2021 he was ill enough to go to the ED due to COVID symptoms and was admitted to the general medicine floor of our hospital.
4/1/2021 in the morning: nauseous, dizziness, sore throat. In the afternoon: chills and hot flashes alternating . All day extremely painful arm  4/2/2021 morning nauseous. All day hot flashes. Pain injection site.  4/3/2021 all day hot flashes, loss of smell. Mild pain injection site.   No fever any of those days
Patient had completed initial 2 vaccine series with Moderna and was scheduled for the 3rd additional dose.   Patient was accidentally given the Pfizer vaccine for the 3rd dose.
Swollen arm (not just very local) mom states twice the size of other arm. Mom wants report as "he is now sensitive to many things".
About 12 or 13 hours after my vaccination I started having severe flu like symptoms.  I got vaccinated at about 1am sunday morning , symptoms started between 1 and 2pm sunday afternoon. 101.5 fever Nausea, vomiting Severe headache body aches Had trouble hydrating while this was going on. Nausea was bad enough to cause me to vomit plain drinking water. Luckily, that passed. I self treated with ibuprofen and gatorade mixed with water. I had these symptoms til about 1 or 2am monday early morning. I had a good nights rest and took the day off from work on monday to recover.  In spite of this I would get a booster in necessary. A few hours of flu symptoms is preferable to getting sick with covid,
8 weeks after shot, I had severe headaches, blurred vision, leg weakness and thought process not clear. This all continued until now. I am out of work at different times and have leg spasms most nights. I am on pain medication.
After getting my booster shot, the following morning I experienced an increased heart rate between (110-119) that would not come down with breathing exercises. My heart rate remained high at rest the entire day. I also had chest tightness which felt like pressure behind my sternum sometimes on the right side and sometimes on the left side.  After a day, my heart rate came down but stayed in the 100-108 range. On Day 3, my heart rate at rest has come down from 100, however, it is still not at my usual range 75-89. I did 25-30min of moderate exercise on Day 3 and noted that the chest tightness/pressure increased with exertion, however, it resolved after resting less than 10 mins.   I also had fatigue and headache which I would consider normal side effects the day after my third dose, which subsides within 24 hours. I took 200mg of ibuprofen mid-afternoon.
I had no AE to the vaccine but in 1/17 I tested positive to COVID-19.
Information has been received from a pharmacist referring to a 4 year old patient. On an unknown date between 16-JUL-2015 and 23-JUL-2015 the patient was vaccinated with PROQUAD (Merck), dose 1 (lot number unknown), 0.5 ml once intramuscularly (Inappropriate schedule of drug administration, incorrect route of drug administration). No adverse effects reported. The outcome was unknown. Additional information has been requested.
Information has been received from a medical technologist concerning a pt who was vaccinated and subsequently, developed atypical rash. The reporter expressed concern with the lot #. Two additional pts were reported with similar incidents after having been vaccinated with the same lot #. Additional information has been requested.
headache; chills; pain; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache), CHILLS (chills) and PAIN (pain) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included DIHYDRALAZINE SULFATE, HYDROCHLOROTHIAZIDE, RESERPINE, TRIAMTERENE (NO 0) for an unknown indication.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Mar-2021, the patient experienced HEADACHE (headache), CHILLS (chills) and PAIN (pain). At the time of the report, HEADACHE (headache), CHILLS (chills) and PAIN (pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
A non-serious spontaneous report of administration of expired FLUMIST was received from a health professional concerning a six-year-old female. Neither relevant medical history nor concomitant medications have been reported for this patient. The product expired on 22-Jan-2012. On 27-Jan-2012, expired FLUMIST was administered to the patient. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved.
A 26 year old female patient experienced flu like symptoms and lymphadenopathy while receiving RabAvert therapy. She received RabAvert 1 ml intramuscularly on 07/24/04 and 07/14/04 for pre exposure prophylaxis. The patient had no past medical history. Concomitant medications consisted of Ortho Tri-cyclen and Chlopheniramine. On 07/14/04, the patient experienced flu like symptoms including feeling warm, an achiness all over, tiredness and malaise that lasted three days. On 07/14/04, she also noticed a slight enlargement of the left axillary lymph node, which was the same side where she received her RabAvert injection. Follow up received 08/16/04: The patient received RabAvert injections on 07/07/04, 07/14/04 and 07/28/04 in the left deltoid. A week following the second RabAvert injection (07/21/04) the patient experienced general malaise, swollen axillary lymph nodes (size of an egg), inability to left her arm and flu like symptoms. She was instructed to take Tylenol after the next RabAvert injection on 07/28/04. No adverse effects were reported after the third injection. The events resolved within approximately 10 days.
A report has been received from a Health Professional concerning a 2 year old, female subject, who had been receiving FLUMIST QUADRIVALENT (intranasal). The patient's medical history included asthma. FLUMIST QUADRIVALENT (intranasal) started on 10-Oct-2014. It was reported that patient with history of asthma received FLUMIST QUADRIVALENT on 10-Oct-2014 which started on 10-Oct-2014. The outcome of the event of patient with history of asthma received FLUMIST QUADRIVALENT on 10OCT2014 is unknown. The report was considered to be non-serious.
pt states that she began feeling sleepy and had a very heavy feeling.  She woke up w/ severe pain that started on under her left arm and went down to her foot that lasted for about 10 minutes.  She had headache, nausea, chills, and fatigue that lasted all day.    She had a funny sensation in the back of her head and her arm felt very heavy.  Today on 3/11/2021 she is feeling better but she like she had something moving under her skin on her left shoulder.   Pt has taken Tylenol for her pain and already has an appt scheduled tomorrow at 1 PM w/ her PCP.
Pt immunized on 09/10/97 for Varivax. was exposed by a pt who also had varivax at the Health Dept. Pt developed approx. 25 lesions
After the flu shot, patient walked away. Then he felt muscle spasms, knee weakness and back pain.
One week after patient received vaccine she developed an itchy, tingling rash down entire right arm.  Diagnosed with Brachioradial pruritis.  This rash continues to persist 7 weeks after onset.
Administered only the diluent; Administered only the diluent; This case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) (batch number 3BD9E, expiry date 6th April 2023) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK receipt date: 17-Oct-2022 Reporter's comment: The nurse reported that they were uncertain of which patient might had received this vaccination as it occurred between 23rd October 2021 and 5th November 2021. The patient's information asked but not available. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up via email. Additional supportive information: The patient was administered only diluent component of Shingrix without using the powder portion, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
the patient was administered an improperly stored dose of PNEUMOVAX 23; This initial spontaneous report as received from a licensed practical nurse (LPN) referring to a patient of unknown age and unknown gender. Information about pertinent medical history, drug reactions/allergies and concomitant medication was not reported.  On 31-JUL-2019, the patient was vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (lot# S004548 with expiration date 12-AUG-2020, dose detail and route were not reported) for prophylaxis. The pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was administered with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23 SYRINGE (DEVICE)). The vaccine experienced improperly stored and was stored at 47.3 Fahrenheit degrees for 20 minutes. There was no previous temperature excursion. The call was because of a data logger involved. For pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23 SYRINGE (DEVICE)), the lot number was reported as S004548 and the serial number was not available. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.  devicelotnumber: S004548; expirationdate: 12-AUG-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Unknown; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
Confusion, Myalgia, Diarrhea, Brain FOG, CRAMPING, MUSCLE PAIN, FATIGUE, INJECTION SITE PAIN, DIARRHEA Narrative:
This spontaneous report was received from a back office lead referring to a 21-year-old patient of unknown gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 23-FEB-2016, the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB lot # L035881, expiration date: 26-JUN-2017, 1 ml, intramuscularly, in right deltoid (a dose number was not provided). There was no adverse effect reported. This is one of several reports received from the same reporter. Additional information has been requested.